This project will support the establishment of an innovation research and development (R&D) centre and a commercial scale, good manufacturing practices (GMP) manufacturing facility in Edmonton, Albert...
Entos Pharmaceuticals Inc.
14 enregistrements totalisant 88,806,102.07 $ CAN, selon les données ouvertes officielles du gouvernement du Canada.
Intégrer ce graphique
Registre des lobbyistes — correspondance possible correspondance par nom
Une organisation portant ce nom figure dans 38 enregistrements de lobbying fédéral (0 actuellement actifs), entre 2020 et 2026.
946789-367391-15 946789-367391-14 946789-367391-13
Correspondance automatique par nom d'organisation; une autre organisation du même nom est possible. Le Registre des lobbyistes fait foi. Le lobbying est légal et encadré — ceci est du contexte, pas une allégation.
Par ministère
| Innovation, Sciences et Développement économique Canada | $62,000,000 | 1 enregistrement |
| Conseil national de recherches Canada | $26,798,300 | 12 enregistrements |
| Affaires mondiales Canada | $7,802 | 1 enregistrement |
Enregistrements
Entos has developed Covigenix VAX-001, a DNA Proteo-Lipid Vehicle (PLV) vaccine intended for the prevention of COVID-19 infection by SARS-CoV-2. In this project, Entos will advance the VAX-001 vaccine...
Entos has developed Covigenix VAX-001, a DNA Proteo-Lipid Vehicle (PLV) vaccine intended for the prevention of COVID-19 infection by SARS-CoV-2. In this project, Entos will advance the VAX-001-1c biva...
Entos has developed Covigenix VAX-001, a DNA Proteo-Lipid Vehicle (PLV) vaccine intended for the prevention of COVID-19 infection by SARS-CoV-2. In this project, Entos will advance the VAX-001 vaccine...
Seasonal and pandemic influenza continue to pose substantial threats to public health and highly pathogenic strains such as H5N1 carry the potential for devastating outbreaks. The Firm proposes to dev...
In partnership with a large Multinational Pharmaceutical Partner, the Firm will evaluate the safety and effectiveness of its Fusogenix formulations optimized for delivery of genetic medicines to the t...
As part of the international consortium project “NPmsDNA2024: Development of in vivo targeted non-viral gene therapies” this project will focus on leveraging Entos’ Fusogenix PLV formulations optimize...
The goal of this project is to establish a method to synthesize Fusogenix DNA lipid nanoparticles using a single step manufacturing process. To achieve this, we will evaluate a number of methods to in...
This project utilizes the Entos Fusogenix DNA delivery platform to rapidly develop, validate, manufacture and deploy countermeasures to protect the majority of the Canadian population from SARS-CoV-2...
As part of Multinational Corporate Collaboration Program, the project “Fusogenix Formulation Development for Safe and Potent Delivery of Nucleic Acid Cargoes in the Eye” will focus on the evaluation o...
The purpose of the Canadian International Innovation Program (CIIP) contribution agreement is to support Canadian SMEs identify international partners in CIIP target countries for industrial research...